Cardiovascular Systems (CSI; St. Paul, Minnesota) is gaining even more headway with its Diamondback 360° System as the device is set to be evaluated in its treatment of coronary arteries. The company recently reported that it had enrolled its first patients in its Orbit II Investigational Device Exemption clinical trial. (Medical Device Daily)